Safety of Iron Sucrose in Liver Disease with Hyperammonemia and Anemia

Introduction to Safety Considerations

In patients with severe hyperammonemia, nutritional protein support (including iron) may need to be deferred for 24-48 hours until hyperammonemia is controlled, as recommended by Clinical Nutrition guidelines 1, 2
When protein administration (including iron) is commenced in patients with elevated ammonia, arterial ammonia levels should be monitored to ensure no pathological elevation occurs, according to Clinical Nutrition guidelines 1, 2

The maximum single dose of iron sucrose is 200 mg, administered over 10 minutes, as stated in Gut guidelines 5, 6
Test doses are not required for iron sucrose, unlike iron dextran, but are recommended for patients with a history of sensitivities to IV iron preparations, as recommended by the Journal of the National Comprehensive Cancer Network 7
Common adverse effects include hypotension, flushing, abdominal cramps, and arthralgias/myalgias, as reported in Anaesthesia 8
Anaphylaxis may occur with IV iron preparations, so resuscitation facilities should be available during administration, as advised in Gut guidelines 5

If there are concerns about IV iron in a patient with severe hyperammonemia, consider deferring iron therapy until ammonia levels are better controlled, as recommended by Clinical Nutrition guidelines 1, 2
For patients with hyperammonemia, monitor ammonia levels before and after iron administration, as advised in Clinical Nutrition guidelines 1, 2

Iron sucrose (Venofer) has a well-established safety profile with relatively fewer serious adverse effects compared to other intravenous iron preparations such as iron dextran, as reported in the American Journal of Kidney Diseases 3
Monitor vital signs during and after infusion to detect potential reactions, as recommended by Praxis Medical Insights 4